Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol 1.8 μg/dL: Results From the MOMENTUM Study
Monday, June 15, 2026 1 min read
Key Takeaway: The MOMENTUM Study results were presented at the Endocrine Society Annual Meeting, highlighting the characterization of individuals with resistant hypertension and their cortisol levels post-dexamethasone suppression test. The findings may provide valuable insights into managing this condition. The study emphasizes the importance of cortisol measurements in understanding hypertension resistance.
Price reaction · baseline $83.16 (2026-06-15T17:00:00.000Z) · hit during market hours · 5 other CORT headline(s) in the window, move may be shared
day 0 close · peak
0%
Market Sentiment Analysis
POSITIVE FACTORS
Presentation at a prominent scientific meeting.
Focus on a significant health issue: resistant hypertension.
Potential for new insights into cortisol levels and hypertension.
Full Press Release Details
Presented : Endocrine Society (ENDO) Annual Meeting, 15 June 2026, Chicago, IL
Presenter : Bradley Eilerman, MD, MHI
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
Download Poster
The post Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol <1.2, 1.2–1.8, and >1.8 μg/dL: Results From the MOMENTUM Study appeared first on Corcept Therapeutics .
Frequently Asked Questions
What was presented at the ENDO Annual Meeting?
The MOMENTUM Study results on resistant hypertension and cortisol levels were presented.
Who presented the MOMENTUM Study findings?
Dr. Bradley Eilerman, MD, MHI, presented the findings.
What is the focus of the MOMENTUM Study?
The study focuses on individuals with resistant hypertension and their cortisol levels.
When was the ENDO Annual Meeting held?
The meeting took place on 15 June 2026 in Chicago, IL.